Search

Author/Creator Hartung, Hans-Peter

11. A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. (25th August 2020)

Authors:
Giovannoni, Gavin; Knappertz, Volker; Steinerman, Joshua R.; Tansy, Aaron P.; Li, Thomas; Krieger, Stephen; Uccelli, Antonio; Uitdehaag, Bernard M.J.; Montalban, Xavier; Hartung, Hans-Peter; Pia Sormani, Maria; Cree, Bruce A.C.; Lublin, Fred; Barkhof, Frederik
Journal:
Neurology
Issue:
Volume 95:Number 8(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

12. Activation of Wnt signaling promotes hippocampal neurogenesis in experimental autoimmune encephalomyelitis. Issue 1 (December 2016)

Authors:
Schneider, Reiner; Koop, Barbara; Schröter, Friederike; Cline, Jason; Ingwersen, Jens; Berndt, Carsten; Hartung, Hans-Peter; Aktas, Orhan; Prozorovski, Tim
Journal:
Molecular neurodegeneration
Issue:
Volume 11:Issue 1(2016)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

16. Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. (12th September 2017)

Authors:
Havrdova, Eva; Arnold, Douglas L.; Cohen, Jeffrey A.; Hartung, Hans-Peter; Fox, Edward J.; Giovannoni, Gavin; Schippling, Sven; Selmaj, Krzysztof W.; Traboulsee, Anthony; Compston, D. Alastair S.; Margolin, David H.; Thangavelu, Karthinathan; Rodriguez, Claudio E.; Jody, Darlene; Hogan, Richard J...
Journal:
Neurology
Issue:
Volume 89:Number 11(2017)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

17. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. (12th September 2017)

Authors:
Coles, Alasdair J.; Cohen, Jeffrey A.; Fox, Edward J.; Giovannoni, Gavin; Hartung, Hans-Peter; Havrdova, Eva; Schippling, Sven; Selmaj, Krzysztof W.; Traboulsee, Anthony; Compston, D. Alastair S.; Margolin, David H.; Thangavelu, Karthinathan; Chirieac, Madalina C.; Jody, Darlene; Xenopoulos, Pano...
Journal:
Neurology
Issue:
Volume 89:Number 11(2017)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

18. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. (8th November 2016)

Authors:
Giovannoni, Gavin; Cohen, Jeffrey A.; Coles, Alasdair J.; Hartung, Hans-Peter; Havrdova, Eva; Selmaj, Krzysztof W.; Margolin, David H.; Lake, Stephen L.; Kaup, Susan M.; Panzara, Michael A.; Compston, D. Alastair S.
Journal:
Neurology
Issue:
Volume 87:Number 19(2016)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

19. ALEMTUZUMAB PERSISTENTLY SLOWS BRAIN VOLUME LOSS IN RRMS. Issue 12 (15th November 2016)

Authors:
Coles, Alasdair; Arnold, Douglas; Barkhof, Frederik; Filippi, Massimo; Hartung, Hans-Peter; Havrdova, Eva; Selmaj, Krzysztof; Margolin, David; Thangavelu, Karthinathan; Schippling, Sven
Journal:
Journal of neurology, neurosurgery and psychiatry
Issue:
Volume 87:Issue 12(2016)
Page Start:
e1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗